Levamisole-induced vasculitis (LIV) is becoming an increasingly common entity secondary to both rising cocaine use in the UK and high levels of adulteration of cocaine with various contaminants. We report the first documented case of LIV secondary to adulterated cocaine in Ireland, which presented as a 6-year history of recurrent vasculitis of unknown aetiology. Classically, LIV is diagnosed by a combination of positive ANCA serology and agranulocytosis however, given the frequency of cocaine use, we urge acute physicians to consider the diagnosis in cases of typical retiform (angulated) purpura in association with a history of cocaine use.

[download-attachments container="div" style="list" display_icon="1" display_count="1" display__size="0"]

References

1. EU Drug Market Report; A strategic analysis. EMCDDA Publications Office of the European Union, 2013. (updated 2013, cited 28th November 2015) Available from: http://www.emcdda.europa.eu/
2. Boyle M, Carroll L, Clarke K et al. What’s the deal? Trends in Irish street-level heroin and cocaine 2010-2012. Drug Testing and Analysis, 6 (9). (2014) pp. 953-958.
3. Gross R, Brucker J, Bahce-Altuntas A et al. A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine. Clinical Rheumatology, October 2011, Volume 30, Issue 10, pp 1385-1392
4. Carter M, Amirhaeri S. P-ANCA-Associated Vasculitis Caused by Levamisole-Adulterated Cocaine: A Case Report. Case Reports in Emergency Medicine, Volume 2013, Article ID 878903.
5. Nolan A, Jen K-Y. Pathologic manifestations of levamisoleadulterated cocaine exposure. Diagnostic Pathology 2015, 10:48
6. Pearson T, Bremmer M, Cohen J et al. Vasculopathy related to cocaine adulterated with levamisole: A review of the literature Dermatology Online Journal 18 (7): 1
7. Lee K, Ladizinski B, Federman D. Complications Associated With Use of Levamisole-Contaminated Cocaine: An Emerging Public Health Challenge. Mayo Clin Proc. 2012 Jun; 87(6): 581–586